Skip to main content
MENU
CLOSE

HypoPARA Newsroom

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

https://investors.ascendispharma.com/news-releases/news-release-details/fda-accepts-priority-review-ascendis-pharmas-nda-transcontm-pth

If you want to be in the know about what’s going on in the world of HypoPARA, you’ve come to the right place. Be sure to check back regularly to get the latest news updates.

News

STATEMENT FROM DR MANNSTADT. VISIT HIS WEBSITE https://scholar.harvard.edu/mannstadt/natpara-recall

REMEMBER
This information is provided for educational purposes only. It should not be used for diagnostic or treatment purposes. If you wish to obtain more information about this disorder, please contact your personal physician.